43
Participants
Start Date
August 31, 2014
Primary Completion Date
May 15, 2015
Study Completion Date
July 10, 2019
Oprozomib
Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
Midazolam
Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
University of Colorado Anschutz Medical Campus, Aurora
Winship Cancer Institute, Atlanta
Henry Ford Hospital, Detroit
Mary Crowley Cancer Research Centers - Medical City, Dallas
University of Texas MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, LLC, San Antonio
Huntsman Cancer Institute, Salt Lake City
Lead Sponsor
Amgen
INDUSTRY